



Media Release: Sydney, Australia: 9 January, 2012.

## **PHEBRA SIGNS DISTRIBUTION AGREEMENT FOR DIGIFAB™**

The Australian pharmaceutical company, Phebra, today announced it had signed an exclusive distribution agreement with Protherics Medicines Development Ltd, a BTG International group company, for the distribution rights in Australia and New Zealand for DigiFab™ (digoxin immune fab (ovine)), an antidote for the treatment of patients suffering life-threatening digoxin toxicity.

Although DigiFab™ has not received marketing approval in Australia or New Zealand, Phebra's Chief Executive Officer, Dr Mal Eutick, commented that the company intends to pursue marketing authorisation in these countries.

BTG is an international specialist healthcare company, developing and commercialising products targeting critical care, cancer and other disorders.

Phebra is an Australian-based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe.

***At Phebra we create critical medicines that save and improve lives.***

Media contact:

The Premier Communications Group, +61 2 92473337

[info@premiercomms.com.au](mailto:info@premiercomms.com.au)